In March 2022, the National Medical Insurance Bureau issued a notice requesting that,
First, according to the procedure, the new coronavirus antigen detection reagents and corresponding detection items are temporarily included in the catalogue of basic medical insurance services in this province.
. The relevant expenses incurred by the insured in the designated primary medical institutions shall be paid according to the current regulations of the overall planning area, and the expenses for purchasing testing reagents in designated retail pharmacies may be paid by personal accounts;
Second, timely adjust the treatment drugs for COVID-19 included in the scope of medical insurance payment.
Half a year later, 343 kinds of drugs, such as the first domestic COVID-19 oral drug Azvudine Tablets, officially passed the formal examination and were included in the List of Declared Drugs for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 2022.
With the implementation of "Class B Management" for novel coronavirus's infection, can COVID-19 drugs and hospitalization expenses previously included in medical insurance be reimbursed? In order to cope with the new epidemic situation, Anhui, Fujian Jinjiang and other places have made clear the proportion of reimbursement for medical insurance in COVID-19, and Beijing, Shaanxi and other places have temporarily included the new crown treatment drugs in the scope of medical insurance reimbursement.
Anhui: The reimbursement rate of outpatient expenses for infection in COVID-19 is 70%.
According to the news of Anhui Provincial Medical Insurance Bureau,1February 29th, Anhui Provincial Medical Insurance Bureau, Anhui Provincial Department of Finance and Anhui Provincial Health and Health Committee jointly issued an urgent notice on doing a good job in the outpatient treatment of novel coronavirus infection, clarifying that the medical expenses incurred by the insured during the ordinary outpatient (emergency) treatment of COVID-19 infection in the co-ordination area, which meet the Covid-19 pneumonia diagnosis and treatment plan and other regulations, are included in the scope of payment of the basic medical insurance co-ordination fund, and there is no deductible and reimbursement limit.
Designated medical institutions that have opened the settlement service of the basic medical insurance co-ordination fund are temporarily included in the overall settlement scope of COVID-19 infection outpatient service; The medical category of "COVID-19 Outpatient Service (1 102)" was unified to settle the outpatient expenses of COVID-19 infection.
Hebei Sanhe released a clear paper on the medical insurance reimbursement policy for Covid-19 infected people
According to the news of "Civilized Three Rivers" in WeChat official account, the sanhe city Medical Security Bureau issued the "Clear Paper on the Policy of Medical Insurance Reimbursement for Covid-19 Infected Persons" on February 1 1/,which clarified that the annual threshold for co-ordination of medical insurance outpatient service for employees is 100 yuan, and the proportion of co-ordination fund payment is 60% under the age of 45, and the annual payment limit is 2,000 yuan. Over 45 years old (inclusive), the overall fund payment ratio is 60%, and the annual payment limit is 3,000 yuan; The proportion of retirees' overall fund payment is 70%, and the annual payment limit is 4000 yuan.
The reimbursement policy for residents' medical insurance outpatient service as a whole is that within an insured year, the insured persons go to the designated medical institutions with the hospitalization qualification of urban and rural residents in the overall planning area for outpatient treatment, the annual Qifubiaozhun for outpatient service as a whole is 50 yuan, the proportion of payment from the overall planning fund is 50%, and the annual payment limit is 60 yuan. From 2023 1 month 1 day, the outpatient deductible line will be cancelled and the annual payment limit will be increased to 80 yuan/year.
In addition, there are corresponding regulations on hospitalization reimbursement in the medical insurance co-ordination area for employees and residents.
Jinjiang, Fujian: outpatient service and hospitalization can be reimbursed.
According to Jinjiang News Network, Jinjiang City, Fujian Province issued a notice on medical insurance reimbursement after COVID-19 infection: in terms of outpatient service, insured persons can enjoy general outpatient treatment if they seek medical treatment in designated primary medical institutions. In the township hospitals (community health service centers), the reimbursement rate is 70%, and the maximum payment limit is 420 yuan; For medical treatment in designated village-level medical institutions in the city, the reimbursement rate is 50%, and the maximum payment limit is 50 yuan (single reimbursement limit 10 yuan). In terms of hospitalization, the basic medical insurance for medical expenses incurred in designated medical institutions in other provinces of the city is reimbursed by 80% of the reimbursement amount in the city, and the basic medical insurance for medical expenses incurred in designated medical institutions outside the province is reimbursed by 60% of the reimbursement amount in the city.
Shandong: Online consultation of symptoms in COVID-19 is included in medical insurance reimbursement.
According to the website of Shandong Medical Insurance Bureau1February 28th, Shandong Medical Insurance Bureau and Shandong Provincial Health and Wellness Committee recently jointly issued the Notice on Doing a Good Job in the Medical Insurance Service for Internet Infection in novel coronavirus, pointing out that the Internet diagnosis fee for related symptoms in COVID-19 is included in the basic medical insurance payment scope, which is consistent with the offline reimbursement policy. The medical insurance department should timely settle and pay the internet plus medical expenses, strengthen the intelligent audit, and promote the rational and standardized use of medical insurance funds.
Beijing: Naimatvir tablets/ritonavir tablets and six other drugs are temporarily included in medical insurance.
In order to cope with the new epidemic situation, with the approval of the National Medical Insurance Bureau, Beijing Medical Insurance Bureau temporarily included six drugs, namely compound paracetamol and amantadine hydrochloride capsules, compound paracetamol and ephedrine hydrochloride oral liquid, pediatric paracetamol, anka Huang Min capsules, clofen Huang Min tablets and ambroxol oral solution, into the scope of drug reimbursement of Beijing medical insurance and industrial injury insurance, and the reimbursement ratio was implemented according to Class A drugs. It will be implemented from 20221February 18 and will be valid until March 18, 2023.
In addition, in order to increase the treatment of patients who may develop into severe or critical illness after COVID-19's infection, recently, Naimatvir Tablets/Ritonavir Tablets have also been included in the scope of reimbursement of medical insurance drugs in Beijing, and the reimbursement rate of community hospitals in Beijing is 90%.
Shaanxi: 234 kinds of COVID-19 drugs were temporarily included in medical insurance.
According to the news of "Healthy Shaanxi Release"1February 22nd,1February 2nd1day, Shaanxi Provincial Medical Security Bureau, Shaanxi Provincial Health and Wellness Committee and Shaanxi Provincial Taxation Bureau of State Taxation Administration of The People's Republic of China jointly issued the Notice on Further Improving the Medical Security Work for Current Epidemic Prevention and Control. The confirmed and suspected patients will use 107 kinds of Chinese patent medicines recommended in the Notice of Shaanxi Provincial Health and Wellness Committee Shaanxi Provincial Administration of Traditional Chinese Medicine on Printing and Distributing the Prevention Plan and Treatment Plan of Covid-19 Infection in Shaanxi Province (Third Edition) (No.53 [2022] of Shaanxi Traditional Chinese Medicine) and two kinds of Chinese patent medicines with strong pertinence and obvious treatment effect selected by experts organized by the Provincial Food and Drug Administration and the Provincial Health and Health Commission.
Hubei: 36 kinds of COVID-19 drugs were temporarily included in medical insurance.
Hubei Provincial Medical Insurance Bureau1February 29th news, with the approval of the National Medical Insurance Bureau, since February 29th, 2022, 36 kinds of Covid-19 drugs, such as pediatric paracetamol and compound pholcodine syrup, have been temporarily included in the reimbursement scope of medical insurance in Hubei Province, and the reimbursement ratio is implemented according to Class A drugs.
Yunnan: 4 1 drug has been temporarily included in medical insurance.
Yunnan Medical Insurance Bureau1February 30th news, 4/KLOC-0 drugs such as "Sangju Yinqiao Powder" in the Catalogue of Drugs for Infected Persons in Covid-19, Yunnan Province (Trial 1st Edition) have been temporarily included in the scope of medical insurance payment, and they are managed according to Class A drugs, which further meets the people's demand for medical treatment and reduces the burden of COVID-19 infected patients.
Guangxi: 15 kinds of COVID-19 drugs can be covered by medical insurance.
According to Guangxi News Network, in order to further protect the people's drug demand, the Medical Security Bureau of the autonomous region temporarily included 15 kinds of drugs such as exogenous febrile tuberculosis granules into the payment scope of the basic medical insurance fund of the whole region, and reimbursed them according to Class A drugs of medical insurance, which will be implemented from February 22, 2022 to March 22, 2023.